Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today that
Chief Executive Officer and Vice Chair Christoph Westphal, M.D., Ph.D.
will give the keynote address at the annual Charité
Hospital/University of Berlin scientific symposium. The talk will be on
Tuesday, January 22 at 5:00 pm GMT.
“It was an honor to be invited by Professor
Detlev Ganten, CEO of the Charité Medical
School, to present at their annual scientific symposium,”
said Westphal. “The Charité
is one of the most famous hospitals in Continental Europe and is
surrounded by extremely talented scientists. My talk will focus on
developing new therapies from academic discoveries, with particular
emphasis on creating drugs that target the sirtuins, genes associated
with aging.”
“Christoph has demonstrated visionary
leadership and a proven ability to take cutting-edge research from
academic medical centers into the biotech sector, first with Alnylam and
RNA interference where key discoveries were made in Germany, and now
with Sirtris regarding diseases of aging,”
said Professor and Charité Chief Executive
Officer Detlev Ganten.
The annual Charité symposium is attended by
more than 500 scientists, doctors, and politicians, including the
leadership of the biomedical sector in Germany. Speaking at this year’s
event are Dr. Ganten, Senator Juergen Zoellner, and Dr. Westphal. The
event is hosted by Johanna Quandt and the Quandt family, owners of BMW
and longtime lead supporters of the Charité
Hospital.
The Charité was recently ranked the top
university medical school in Germany, as well as the top German medical
school in impact and grant money. It has an annual budget of $1.5
billion USD. The medical school has been home to eight Nobel Laureates,
including Robert Koch, Otto Warburg, and Rudolf Virchow, as well as many
of the leading biomedical scientists in Germany.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators for diseases of aging, the progress and
results of pre-clinical and clinical studies of SIRT1 activators,
development of first-in-class therapeutics that modulate sirtuins, and
the potential of sirtuin modulators to receive regulatory approval.
These forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack of
results that would provide a basis for predicting whether any of the
Company's product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results, the
Company's potential inability to initiate and complete pre-clinical
studies and clinical trials for its product candidates, the fact that
none of the Company's product candidates has received regulatory
approvals, the potential inability of the Company to gain market
acceptance of the Company's product candidates, and those other risks
factors that can be found in the Company's filings with the Securities
and Exchange Commission. Actual results may differ materially from those
Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.